APA (7th ed.) Citation

F, E., S, B., P, A., PY, S., CY, L., AM, A., . . . P, C. (2018). Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. BMC ophthalmology, 18(1), 20. https://doi.org/10.1186/s12886-018-0688-3

Chicago Style (17th ed.) Citation

F, Elwes, Borooah S, Aspinall P, Sim PY, Loo CY, Armbrecht AM, Dhillon B, and Cackett P. "Clinical Outcomes of Switching to Aflibercept Using a Pro Re Nata Treatment Regimen in Patients with Neovascular Age-related Macular Degeneration Who Incompletely Responded to Ranibizumab." BMC Ophthalmology 18, no. 1 (2018): 20. https://doi.org/10.1186/s12886-018-0688-3.

MLA (9th ed.) Citation

F, Elwes, et al. "Clinical Outcomes of Switching to Aflibercept Using a Pro Re Nata Treatment Regimen in Patients with Neovascular Age-related Macular Degeneration Who Incompletely Responded to Ranibizumab." BMC Ophthalmology, vol. 18, no. 1, 2018, p. 20, https://doi.org/10.1186/s12886-018-0688-3.